US · Healthcare · Biotechnology
EPS came in at 0.84 against a street estimate of -0.55 — a beat of 252.7%.
Analysts rate Edgewise Therapeutics Inc a strong buy (12 buy, 2 hold, 0 sell out of 14) with an average price target of $54.00.
| Fund | Stake |
|---|---|
| Orbimed Advisors LLC | 14.29% |
| Paradigm Biocapital Advisors LP | 9.41% |
| RA Capital Management, LLC | 7.73% |
| BlackRock Inc | 6.08% |
| Jupiter Topco LLC | 5.59% |
| FMR Inc | 5.05% |
| Novo A/S | 4.93% |
| Driehaus Capital Management LLC | 4.35% |
| Document | Date |
|---|---|
| Quarterly report · Q3 2026 HEADLINE NUMBERS • Edgewise Therapeutics reported net income of $1,059,811 thousand for the nine months ended September 30, 2026, compared with a net | 2026-11-04 |
| Results announced · Q4 2026 HEADLINE NUMBERS • Third-quarter 2026 net income was $1,166.2 million, or $10.71 per basic share and $9.65 per diluted share, versus a net loss of $4 | 2026-11-04 |
| Quarterly report · Q2 2026 EDGEWISE THERAPEUTICS, INC. — Q2 2026 SUMMARY HEADLINE NUMBERS • Cash & Equivalents: $72.3 million as of June 30, 2026 (down from $61.1 million Dece | 2026-08-06 |
| Results announced · Q3 2026 EDGEWISE THERAPEUTICS Q2 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Cash Position: $460.7 million as of June 30, 2026; pro forma balance of $ | 2026-08-06 |
| Acquisition completed · Q3 2026 EDGEWISE THERAPEUTICS, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Completed asset sale of sevasemten compound and muscular dystrophy program to Serv | 2026-07-13 |
| Shareholder vote results · Q2 2026 EDGEWISE THERAPEUTICS, INC. - 8-K SUMMARY HEADLINE NUMBERS • Annual Meeting held June 4, 2026 • Company: Edgewise Therapeutics, Inc. (ticker: EWTX, | 2026-06-05 |
| Material agreement · Q2 2026 EDGEWISE THERAPEUTICS, INC. - 8-K SUMMARY HEADLINE NUMBERS • Company selling its neuromuscular program (sevasemten compound) to Servier Pharmaceutic | 2026-06-01 |
| Quarterly report · Q1 2026 EDGEWISE THERAPEUTICS, INC. – Q1 2026 SUMMARY HEADLINE NUMBERS • Cash and cash equivalents: $33.2 million as of March 31, 2026 (down from $61.1 mill | 2026-05-07 |
Readable in the app.
| Announcement | Date |
|---|---|
| Completion of transaction announced with pro forma financials to follow On July 13, 2026, Edgewise Therapeutics, Inc. completed a transaction and issued a press release announcing this completion. The 8-K filing itself provides minimal substantive details about | 2026-07-13 |
| Asset purchase agreement entered into with Servier Pharmaceuticals Edgewise Therapeutics announced on June 1, 2026, that it has agreed to sell its neuromuscular disease program to Servier Pharmaceuticals in a major asset deal. The program centers on sevasem | 2026-06-01 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Edgewise Therapeutics Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.